24th Aug 2015 14:00
Venn Life Sciences Holdings Plc
("Venn" the "Company" or the "Group")
Appointment of Co-Broker
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, is pleased to announce the appointment of Hybridan LLP as the Company's co-broker, with immediate effect. Zeus Capital remains Nominated Adviser and Broker to the Company.
For further information:
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer Jonathan Hartshorn, Chief Financial Officer | Tel: +353 154 99 341 Tel: +353 153 93 269 |
Orla McGuinness, Marketing Manager | Tel: +33 (0)1 30 82 67 07 |
|
|
Zeus Capital (Nominated Adviser and Broker) |
|
Ross Andrews/Andrew Jones/Phil Walker | Tel: 0161 831 1512 |
Dominic Wilson/Alex Davies | Tel: 020 7533 7727 |
|
|
Hybridan LLP (Co-Broker) |
|
Claire Louise Noyce | Tel: 020 3764 2341 |
Walbrook PR Ltd | Tel: 020 7933 8787 or [email protected] |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
Related Shares:
ORPH.L